Zenosense, Inc. (ZENO)
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient. Continue >
Find out which Small Cap Stocks should be on your radar. Get the news and information that moves the markets and our "Ones to Watch"
QualityStocks is committed to protecting investors from unscrupulous characters. Every day we track the content and performance of hundreds of newsletter providers for the benefit of our subscribers. Via the QualityStocks Daily, our subscribers are able to track and measure the latest micro-cap stock picks and see who is making the best recommendations.
The QualityStocks Blog keeps investors up to date on everything related to the Small-Cap and Micro-Cap markets. By visiting our blog, investors also discover emerging companies that they otherwise would not have heard about.
The message boards here at QualityStocks is one of the most highly regulated, no-nonsense forums online today. Investors actively discuss their favorite trading ideas within the NYSE, NASDAQ, AMEX, OTCBB and Pink Sheets markets.
To submit a press release, share a story idea, or give us feedback, contact us.
New to the Game? Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.
Newsletter Editors, looking to get more coverage and grow subscriptions? Get your newsletter covered by The QualityStocks Daily.
At QualityStocks we believe that newsletters, even those out-of-date, are important. Now you can go back to see our previous newsletters and find out what you might have missed.